Belantamab mafodotin for relapsed/refractory multiple myeloma: a real-world observational study update

被引：0

作者：

Hultcrantz, Malin ^{[1
]}

Kleinman, David ^{[2
]}

Vij, Ravi ^{[3
]}

Escalante, Fernando ^{[4
]}

Delforge, Michel ^{[5
]}

Kotowsky, Nirali ^{[6
]}

Bitetti, Jacopo ^{[7
]}

Boytsov, Natalie ^{[6
]}

Camadoo-O'Byrne, Leena ^{[8
]}

Happ, Lindsey Powers ^{[9
]}

Rohman, Mujib ^{[10
]}

Germain, Guillaume ^{[11
]}

Duh, Mei Sheng ^{[12
]}

Laliberte, Francois ^{[11
]}

Mahendran, Malena ^{[11
]}

Urosevic, Ana ^{[11
]}

Lee, Hans ^{[13
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Med, Myeloma Serv, New York, NY USA

[2] Univ Rochester, Flaum Eye Inst, Med Ctr, Rochester, NY USA

[3] Washington Univ, Div Oncol, Sch Med, St Louis, MO USA

[4] Univ Hosp Leon, Dept Hematol, Leon, Spain

[5] Univ Leuven, Leuven, Belgium

[6] GSK, Upper Providence, PA USA

[7] GSK, Zug, Switzerland

[8] GSK, Stevenage, Herts, England

[9] GSK, Collegeville, PA USA

[10] GSK, Windsor, England

[11] Ltee, Grp Anal, Montreal, PQ, Canada

[12] Anal Grp Inc, Boston, MA USA

[13] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma Myeloma, Houston, TX USA

来源：

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2023年 / 23卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-272

引用

页码：S185 / S186

页数：2

共 50 条

[1] Belantamab Mafodotin for Relapsed or Refractory Multiple Myeloma: A Real-World Observational Study Update
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Delforge, Michel
Kotowsky, Nirali
Bitetti, Jacopo
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Happ, Lindsey Powers
Rohman, Mujib
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S504 - S504
[2] Belantamab mafodotin (belamaf) for relapsed/refractory multiple myeloma (RRMM): A real-world observational study update
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Delforge, Michel
Kotowsky, Nirali
Bitetti, Jacopo
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Powers Happ, Lindsey
Rohman, Mujib
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans C.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[3] Belantamab Mafodotin (Belamaf) for Relapsed/Refractory Multiple Myeloma (RRMM): A Real-World Observational Study
Hultcrantz, Malin
Kleinman, David
Vij, Ravi
Escalante, Fernando
Kotowsky, Nirali
Bitetti, Jacopo
Mackay, Christine
Boytsov, Natalie
Camadoo-O'Byrne, Leena
Germain, Guillaume
Duh, Mei Sheng
Laliberte, Francois
Mahendran, Malena
Urosevic, Ana
Lee, Hans C.
[J]. BLOOD, 2022, 140 : 10124 - 10126
[4] A real-world observational study of belantamab mafodotin (belamaf) as a treatment for relapsed/refractory multiple myeloma (RRMM)
Cavo, Michele
Delforge, Michel
Dimopoulos, Meletios
Escalante, Fernando
Hultcrantz, Malin
Kleinman, David
Lee, Hans
Vij, Ravi
Kotowsky, Nirali
Camadoo-O'Byrne, Leena
Bitetti, Jacopo
D'Estrube, Tim
Fry, Mark
Vossen, Carla
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S166 - S167
[5] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience
Hultcrantz, Malin
Orozco, Jennifer
Peterson, Tim J.
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Lu, Sydney X.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Maclachlan, Kylee H.
Chung, David J.
Landau, Heather J.
Shah, Gunjan L.
Lahoud, Oscar B.
Scordo, Michael
Landgren, Ola
Giralt, Sergio
Lesokhin, Alexander
[J]. BLOOD, 2021, 138
[6] Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study
Shragai, Tamir
Magen, Hila
Lavi, Noa
Gatt, Moshe
Trestman, Svetlana
Zektser, Miri
Ganzel, Chezi
Jarchowsky, Osnat
Berger, Tamar
Tadmor, Tamar
Leiba, Merav
Hertzog-Tzarfaty, Katrin
Horowitz, Netanel
Shapira, Michael
Varssano, David
Berger, Yoav
Frenkel, Shahar
Krauthammer, Mark
Avivi, Irit
Luttwak, Efrat
Cohen, Yael C.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2023, 200 (01) : 45 - 53
[7] Real-world analysis of belantamab mafodotin (belamaf): Care patterns in relapsed/refractory multiple myeloma
Patel, Mihir
Locke, Susan C.
Falvey, Caroline
Troy, Jesse D.
Herring, Kris W.
Bolgioni-Smith, Amanda
Doherty, Allison
Elcock, Cherie Howard
Iadeluca, Laura L.
LeBlanc, Thomas William
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[8] Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Single Center Experience
Hultcrantz, Malin
Derkach, Andriy
Hassoun, Hani
Korde, Neha
Maclachlan, Kylee H.
Mailankody, Sham
Patel, Dhwani
Shah, Urvi A.
Tan, Carlyn
Akhlaghi, Theresia
Hamadeh, Issam S.
Chung, David J.
Lahoud, Oscar B.
Landau, Heather
Scordo, Michael
Shah, Gunjan L.
Giralt, Sergio A.
Lesokhin, Alexander M.
Usmani, Saad
[J]. BLOOD, 2022, 140 : 7246 - 7248
[9] Effectiveness and safety of belantamab mafodotin in patients with relapsed or refractory multiple myeloma in real-world setting: The ALFA study
Roussel, Murielle
Texier, Nathalie
Nael, Virginie
Bitetti, Jacopo
Paka, Prani
Kerbouche, Naima
Sail, Lynda
Colin, Xavier
Leleu, Xavier
[J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2024, 113 (03) : 310 - 320
[10] Belantamab mafodotin for relapsed or refractory multiple myeloma
David Gil-Sierra, Manuel
del Pilar Briceno-Casado, Maria
[J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, 28 (06) : 1375 - 1380

← 1 2 3 4 5 →